Precision Biosciences (DTIL) Operating Expenses (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Operating Expenses data on file, last reported at $19.9 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $19.9 million, down 10.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.2 million (down 11.6% YoY), and the FY2025 annual result was $86.4 million, down 8.9% from the prior year.
• Operating Expenses declined to $19.9 million in Q1 2026 per DTIL's latest filing, from $21.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $33.4 million in Q2 2022 and troughed at $19.9 million in Q1 2026.
• A 5-year average of $23.7 million and a median of $22.1 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses sank 38.73% in 2022, then rose 16.22% in 2024.
• A 5-year view of Operating Expenses shows it stood at $22.7 million in 2022, then declined by 3.43% to $21.9 million in 2023, then rose by 16.22% to $25.5 million in 2024, then dropped by 14.86% to $21.7 million in 2025, then decreased by 8.22% to $19.9 million in 2026.
• Business Quant data shows DTIL's Operating Expenses at $19.9 million in Q1 2026, $21.7 million in Q4 2025, and $20.7 million in Q3 2025.